Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s

Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s

291885

Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s

Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease continue without modification.  As specified in trial protocol, the Independent Data Safety Monitoring Board (DSMB) — used in ongoing clinical trials to protect patients and the integrity of study data — reviewed interim safety data for the Anavex 2-73-AD-004 trial (NCT03790709) and its open-label extension, called ATTENTION-AD (NCT04314934), before favoring their continuation. Alzheimer’s,…

You must be logged in to read/download the full post.